Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

The efficacy of rifabutin for rifabutin-susceptible, multidrug-resistant tuberculosis.

Jo KW, Ji W, Hong Y, Lee SD, Kim WS, Kim DS, Shim TS.

Respir Med. 2013 Feb;107(2):292-7. doi: 10.1016/j.rmed.2012.10.021.

2.

Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.

Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, Choi YS, Kim K, Kim J, Shim YM, Koh WJ.

Clin Infect Dis. 2008 Aug 15;47(4):496-502. doi: 10.1086/590005.

3.

[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].

Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H.

Kekkaku. 2003 Oct;78(10):611-7. Japanese.

PMID:
14621568
4.

Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis.

Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, Kim EK, Lee KM, Lee SS, Park JS, Koh WJ, Lee CH, Shim TS.

Am J Respir Crit Care Med. 2010 Jul 1;182(1):113-9. doi: 10.1164/rccm.200911-1656OC.

PMID:
20224066
5.

Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.

Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ.

Clin Infect Dis. 2007 Nov 15;45(10):1290-5.

6.

Surgical treatment to increase the success rate of multidrug-resistant tuberculosis.

Man MA, Nicolau D.

Eur J Cardiothorac Surg. 2012 Jul;42(1):e9-12. doi: 10.1093/ejcts/ezs215.

PMID:
22531273
7.

Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?

Loeliger A, Suthar AB, Ripin D, Glaziou P, O'Brien M, Renaud-Thery F, Crowley S, Williams B, Ridzon R, Granich R, Gilks C.

Int J Tuberc Lung Dis. 2012 Jan;16(1):6-15. doi: 10.5588/ijtld.10.0626. Review.

PMID:
21819645
8.

Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis.

Jo KW, Lee SD, Kim WS, Kim DS, Shim TS.

Int J Tuberc Lung Dis. 2014 Jan;18(1):39-43. doi: 10.5588/ijtld.13.0307.

PMID:
24365550
9.

Representative drug susceptibility patterns for guiding design of re-treatment regimens for multidrug-resistant tuberculosis in Iran.

Tabarsi P, Nooraki A, Mirsaeidi M, Amiri M, Baghaei P, Farnia P, Kazempour M, Heidarnazhad H, Alipanah N, Mansouri D, Masjedi MR.

Respirology. 2008 Jan;13(1):108-11. doi: 10.1111/j.1440-1843.2007.01201.x.

PMID:
18197919
10.

Surgical treatment for multidrug-resistant and extensive drug-resistant tuberculosis.

Kang MW, Kim HK, Choi YS, Kim K, Shim YM, Koh WJ, Kim J.

Ann Thorac Surg. 2010 May;89(5):1597-602. doi: 10.1016/j.athoracsur.2010.02.020.

PMID:
20417785
11.

Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.

Tabarsi P, Chitsaz E, Tabatabaei V, Baghaei P, Shamaei M, Farnia P, Marjani M, Kazempour M, Mansouri D, Masjedi MR, Velayati AA.

Am J Ther. 2011 Sep;18(5):343-9. doi: 10.1097/MJT.0b013e3181dd60ec.

PMID:
20535008
12.

Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis.

Blöndal K, Viiklepp P, Guðmundsson LJ, Altraja A.

Int J Tuberc Lung Dis. 2012 Sep;16(9):1228-33. doi: 10.5588/ijtld.12.0037.

PMID:
22748131
13.

Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis.

Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, Kim EK, Lee KM, Lee SS, Park JS, Koh WJ, Lee CH, Kim JY, Shim TS.

Am J Respir Crit Care Med. 2008 Nov 15;178(10):1075-82. doi: 10.1164/rccm.200801-132OC.

PMID:
18703792
14.

Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.

Park SK, Kim JH, Kang H, Cho JS, Smego RA Jr.

Int J Infect Dis. 2009 Mar;13(2):170-5. doi: 10.1016/j.ijid.2008.06.001.

15.

[Cross-resistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains].

Chikamatsu K, Mizuno K, Yamada H, Mitarai S.

Kekkaku. 2009 Sep;84(9):631-3. Japanese.

PMID:
19860266
16.

Implementation of the INNO-LiPA Rif. TB® line-probe assay in rapid detection of multidrug-resistant tuberculosis in Latvia.

Skenders GK, Holtz TH, Riekstina V, Leimane V.

Int J Tuberc Lung Dis. 2011 Nov;15(11):1546-52, i. doi: 10.5588/ijtld.11.0067.

PMID:
22008771
17.

Multidrug- and extensively drug-resistant tuberculosis, Germany.

Eker B, Ortmann J, Migliori GB, Sotgiu G, Muetterlein R, Centis R, Hoffmann H, Kirsten D, Schaberg T, Ruesch-Gerdes S, Lange C; German TBNET Group..

Emerg Infect Dis. 2008 Nov;14(11):1700-6. doi: 10.3201/eid1411.080729.

18.

Treatment outcome and mortality among patients with multidrug-resistant tuberculosis in tuberculosis hospitals of the public sector.

Jeon DS, Shin DO, Park SK, Seo JE, Seo HS, Cho YS, Lee JY, Kim DY, Kong SJ, Kim YS, Shim TS.

J Korean Med Sci. 2011 Jan;26(1):33-41. doi: 10.3346/jkms.2011.26.1.33.

19.

The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks.

Sirgel FA, Warren RM, Böttger EC, Klopper M, Victor TC, van Helden PD.

PLoS One. 2013;8(3):e59414. doi: 10.1371/journal.pone.0059414. Erratum in: PLoS One. 2015;10(7):e0134190.

20.

Use of rifabutin in the treatment of pulmonary tuberculosis.

Grassi C, Peona V.

Clin Infect Dis. 1996 Apr;22 Suppl 1:S50-4. Review.

Items per page

Supplemental Content

Support Center